National Institute on Drug Abuse; Notice of Closed Meetings, 21300 [2018-09900]
Download as PDF
<![CDATA[
21300
Federal Register / Vol. 83, No. 90 / Wednesday, May 9, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Chronic Fatigue
Syndrome Advisory Committee
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services (HHS) is hereby giving notice
that a webinar meeting of the Chronic
Fatigue Syndrome Advisory Committee
(CFSAC) will take place and open to the
public to listen in via a toll free number.
DATES: The CFSAC webinar will be held
on Wednesday, June 20, 2018, from 9:00
a.m. until 5:00 p.m. and on Thursday,
June 21, 2018 from 9:00 a.m. to 5:00
p.m. (EST).
ADDRESSES: This meeting will be
broadcasted to the public as a webinar.
A webinar is a virtual meeting.
Registration is not required for the
webinar.
SUMMARY:
amozie on DSK3GDR082PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Gustavo Ceinos, MPH, Designated
Federal Officer, Chronic Fatigue
Syndrome Advisory Committee,
Department of Health and Human
Services, 200 Independence Avenue
SW, Room 728F.6, Washington, DC
20201. Please direct all inquiries to
cfsac@hhs.gov.
SUPPLEMENTARY INFORMATION: The
CFSAC is authorized in 42 U.S.C.217a,
Section 222 of the Public Health Service
Act, as amended. The purpose of the
CFSAC is to provide advice and
recommendations to the Secretary of
Health and Human Services (HHS),
through the Assistant Secretary for
Health (ASH), on issues related to
myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS). The issues
can include factors affecting access and
care for persons with ME/CFS; the
science and definition of ME/CFS; and
broader public health, clinical, research,
and educational issues related to ME/
CFS.
The agenda for this meeting, call-in
information and location will be posted
on the CFSAC website https://
www.hhs.gov/ash/advisory-committees/
cfsac/meetings/.
A one hour of public comments via
telephone will be scheduled for the first
and second day of the webinar.
Individuals will have five minutes to
present their comments. Priority will be
given to individuals who have not
provided public comments within the
VerDate Sep<11>2014
17:39 May 08, 2018
Jkt 244001
previous year. We are unable to place
international calls for public comments.
To request a time slot for public
comments, please send an email to
cfsac@hhs.gov by Wednesday, June 13,
2018. The email should contain the
speaker’s name and the telephone
number that will be used for public
comments.
Individuals who would like to
provide written testimony to Committee
members should submit a copy of their
testimony prior to the meeting. It is
preferred, but not required, that the
submitted testimony be prepared in
digital format and typed using a 12pitch font. Copies of the written
testimony must not exceed 5 singlespace pages, and it is preferred, but not
required that the document be prepared
in the MS Word format. Please note that
PDF files, handwritten notes, charts,
and photographs cannot be accepted.
Materials submitted should not include
sensitive personal information, such as
social security number, birthdates,
driver’s license number, passport
number, financial account number, or a
credit or debit card number. If you wish
to remain anonymous, you must specify
this in the document.
The Committee welcomes input on
any topic related to ME/CFS.
Dated: April 27, 2018.
Gustavo Ceinos,
Commander, USPHS, Designated Federal
Officer.
[FR Doc. 2018–09844 Filed 5–8–18; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel
Identification of Biomarkers of HIV–1
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Pathogenesis and Substance Abuse
Comorbidity (R01–Clinical Trials Not
Allowed).
Date: June 6, 2018.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel
Improving Implementation of Seek, Test,
Treat & Retain Strategies Among People Who
Inject Drugs in Low to Middle Income
Countries (R01–Clinical Trial Required).
Date: June 14, 2018.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center. 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute onDrug Abuse, National Institutes of
Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel
Identification of Genetic and Genomic
Variants byNext-Gen Sequencing in NonHuman Animal Models (U01).
Date: June 21, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review,
NationalInstitute on Drug Abuse, NIH,
DHHS, 6001 Executive Blvd., Room 4238,
MSC 9550, Bethesda, MD 20892–9550, 301–
827–5819, gm145A@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: May 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–09900 Filed 5–8–18; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\09MYN1.SGM
09MYN1
]]>Agencies
[Federal Register Volume 83, Number 90 (Wednesday, May 9, 2018)]
[Notices]
[Page 21300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09900]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Identification of Biomarkers of HIV-1 Pathogenesis
and Substance Abuse Comorbidity (R01-Clinical Trials Not Allowed).
Date: June 6, 2018.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Improving Implementation of Seek, Test, Treat &
Retain Strategies Among People Who Inject Drugs in Low to Middle
Income Countries (R01-Clinical Trial Required).
Date: June 14, 2018.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center. 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute onDrug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Identification of Genetic and Genomic Variants
byNext-Gen Sequencing in Non-Human Animal Models (U01).
Date: June 21, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, NationalInstitute
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-827-5819, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: May 4, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-09900 Filed 5-8-18; 8:45 am]
BILLING CODE 4140-01-P
